EA200200831A1 - Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой - Google Patents

Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой

Info

Publication number
EA200200831A1
EA200200831A1 EA200200831A EA200200831A EA200200831A1 EA 200200831 A1 EA200200831 A1 EA 200200831A1 EA 200200831 A EA200200831 A EA 200200831A EA 200200831 A EA200200831 A EA 200200831A EA 200200831 A1 EA200200831 A1 EA 200200831A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical composition
acid
tyoglycolic
monotohycerin
cystein
Prior art date
Application number
EA200200831A
Other languages
English (en)
Other versions
EA004708B1 (ru
Inventor
Енс Кемкен
Бернд Ульрих Рибезель
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0002691A external-priority patent/GB2358799A/en
Priority claimed from GB0019599A external-priority patent/GB2365768A/en
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200200831A1 publication Critical patent/EA200200831A1/ru
Publication of EA004708B1 publication Critical patent/EA004708B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции, включающей пеметрексед, по меньшей мере, один антиоксидант, выбираемый из группы, состоящей из монотиоглицерина, L-цистеина и тиогликолевой кислоты, и фармацевтически приемлемый носитель. Фармацевтическая композиция пригодна для парентерального введения.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200831A 2000-02-04 2001-01-23 Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой EA004708B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0002691A GB2358799A (en) 2000-02-04 2000-02-04 A pharmaceutical composition comprising pemetrexed and an antioxidant
GB0019599A GB2365768A (en) 2000-08-09 2000-08-09 Stable liquid composition containing pemetrexed
PCT/US2001/000648 WO2001056575A1 (en) 2000-02-04 2001-01-23 Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid

Publications (2)

Publication Number Publication Date
EA200200831A1 true EA200200831A1 (ru) 2003-02-27
EA004708B1 EA004708B1 (ru) 2004-06-24

Family

ID=26243579

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200831A EA004708B1 (ru) 2000-02-04 2001-01-23 Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой

Country Status (31)

Country Link
EP (1) EP1265612B1 (ru)
JP (1) JP2003521518A (ru)
KR (1) KR20020081293A (ru)
CN (1) CN1396828A (ru)
AR (1) AR027360A1 (ru)
AT (1) ATE267601T1 (ru)
AU (1) AU3442201A (ru)
BR (1) BR0107958A (ru)
CA (1) CA2399124A1 (ru)
CO (1) CO5280222A1 (ru)
CZ (1) CZ20022654A3 (ru)
DE (1) DE60103512T2 (ru)
DK (1) DK1265612T3 (ru)
DZ (1) DZ3269A1 (ru)
EA (1) EA004708B1 (ru)
ES (1) ES2220716T3 (ru)
HK (1) HK1052461A1 (ru)
HR (1) HRP20020636A2 (ru)
HU (1) HUP0300709A3 (ru)
IL (1) IL150475A0 (ru)
MX (1) MXPA02007191A (ru)
MY (1) MY129450A (ru)
NO (1) NO20023379L (ru)
NZ (1) NZ519727A (ru)
PE (1) PE20011223A1 (ru)
PL (1) PL356705A1 (ru)
PT (1) PT1265612E (ru)
SK (1) SK10982002A3 (ru)
SV (1) SV2002000301A (ru)
TR (1) TR200401436T4 (ru)
WO (1) WO2001056575A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2470500C (en) * 2001-12-28 2012-05-15 Guilford Pharmaceuticals, Inc. Aqueous based pharmaceutical formulations of water-soluble prodrugs of propofol
KR101069128B1 (ko) * 2011-03-10 2011-09-30 건일제약 주식회사 페메트렉시드 또는 그의 염을 포함하는 항산화제-비함유 주사용 용액 형태의 약학적 제제의 제조방법
KR20130122065A (ko) * 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
EP2666463A1 (en) 2012-05-21 2013-11-27 Synthon BV Stabilized liquid composition comprising pemetrexed
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101260636B1 (ko) 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
CN103340826B (zh) * 2013-07-05 2015-09-09 浙江震元制药有限公司 美他多辛注射用组合物及其制备方法
WO2015050230A1 (ja) 2013-10-03 2015-04-09 富士フイルム株式会社 注射液製剤及びその製造方法
KR101703980B1 (ko) 2013-12-30 2017-02-08 주식회사 삼양바이오팜 항산화제를 함유하지 않는 약학 조성물 및 그의 제조방법
WO2015145911A1 (ja) * 2014-03-28 2015-10-01 富士フイルム株式会社 注射液製剤及びその製造方法
WO2016024369A1 (ja) * 2014-08-13 2016-02-18 テバ製薬株式会社 がん治療用医薬組成物
SI3206666T1 (sl) 2014-10-16 2020-04-30 Synthon B.V. Tekoč farmacevtski sestavek, ki obsega pemetreksed
KR101770605B1 (ko) * 2014-11-17 2017-08-23 동아에스티 주식회사 페메트렉시드 또는 그것의 약제학적으로 허용가능 한 염을 함유하는 안정한 약제학적 조성물
KR101919436B1 (ko) * 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법
KR101693675B1 (ko) * 2015-12-14 2017-01-06 주식회사 종근당 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
JP2019094284A (ja) * 2017-11-21 2019-06-20 日本化薬株式会社 ペメトレキセドを含有する注射用溶液製剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) * 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체

Also Published As

Publication number Publication date
AU3442201A (en) 2001-08-14
BR0107958A (pt) 2002-10-29
PT1265612E (pt) 2004-08-31
EA004708B1 (ru) 2004-06-24
CA2399124A1 (en) 2001-08-09
HUP0300709A2 (hu) 2003-07-28
SV2002000301A (es) 2002-06-07
CN1396828A (zh) 2003-02-12
DZ3269A1 (fr) 2001-08-09
HUP0300709A3 (en) 2005-04-28
EP1265612B1 (en) 2004-05-26
PL356705A1 (en) 2004-06-28
KR20020081293A (ko) 2002-10-26
IL150475A0 (en) 2002-12-01
NO20023379L (no) 2002-09-30
PE20011223A1 (es) 2001-12-20
WO2001056575A1 (en) 2001-08-09
NO20023379D0 (no) 2002-07-12
SK10982002A3 (sk) 2003-03-04
HRP20020636A2 (en) 2003-10-31
AR027360A1 (es) 2003-03-26
NZ519727A (en) 2004-04-30
EP1265612A1 (en) 2002-12-18
MY129450A (en) 2007-04-30
CO5280222A1 (es) 2003-05-30
DK1265612T3 (da) 2004-08-09
TR200401436T4 (tr) 2004-07-21
ES2220716T3 (es) 2004-12-16
CZ20022654A3 (cs) 2003-01-15
DE60103512D1 (de) 2004-07-01
HK1052461A1 (en) 2003-09-19
ATE267601T1 (de) 2004-06-15
DE60103512T2 (de) 2005-06-02
JP2003521518A (ja) 2003-07-15
MXPA02007191A (es) 2002-12-09

Similar Documents

Publication Publication Date Title
EA200200831A1 (ru) Фармацевтическая композиция, включающая пеметрексед вместе с монотиоглицерином, l-цистеином или тиогликолевой кислотой
BRPI0412314A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
EA199800563A1 (ru) Антагонисты гормона, высвобождающего гонадотропин
EA200200546A1 (ru) Устойчивый полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способы его получения и фармацевтические применения
EA200300323A1 (ru) ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ)
EA200200938A1 (ru) Фармацевтические композиции, содержащие производные азетидина, новые производные азетидина и их получение
FR2838439B1 (fr) Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant
EA200201271A1 (ru) Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
EA200201179A1 (ru) Производные 2-аминокарбонил-9h-пурина
EA200300248A1 (ru) Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
BG66085B1 (bg) Фенилаланинови производни
BR0008056A (pt) Pirrolocarbazóis e isoindolonas cìclicas fundidas substituìdas
EA200200119A1 (ru) β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ
EA200300450A1 (ru) Фармацевтические растворы соединений модафинила
EA200400819A1 (ru) Парентеральная композиция парацетамола
EA200400690A1 (ru) Нуклеозиды, их препараты и их применение в качестве ингибиторов вирусных рнк-полимераз
PT1204658E (pt) Agonistas benzofurilpiperazina de serotonina
EA200100984A1 (ru) Новые кристаллические формы макролидного антибиотика
ATE371644T1 (de) Neues alkaloidderivat und dieses enthaltende pharmazeutische zusammensetzung
EA200400211A1 (ru) Лиофилизованная композиция 2-метилтиенобензодиазепина
EA200300756A1 (ru) Андрогенные 7-замещенные-11-галогенированные стероиды
GB0130868D0 (en) New compounds
BR0107630A (pt) Composição
ATE282608T1 (de) Chinoxalindionen

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU